Investigating the Effects of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

Authors

JJ Alvarez

Faculty Mentor

David Daberkow

Document Type

Poster

Start Date

10-5-2023 11:15 AM

End Date

10-5-2023 1:00 PM

Location

PUB NCR

Department

Biology

Abstract

Introduction: Oxytocin has been used as a post-treatment for PTSD. Previous research suggests that pre-treatment of intranasal oxytocin attenuates signs of fear in rats; however, the impact of intraperitoneal (i.p) oxytocin pre-treatment on signs of fear in rats is unknown. To further this research, we investigated the specific dose of oxytocin, administered (i.p), that will also alleviate signs of fear in rats. Methods: Male Sprague-Dawley rats, were split into five experimental groups (n=8 per group); 1.) control group treated with vehicle and no foot shock, 2.) shock group treated with vehicle and received foot shock, 3.) low dose group that received 0.03 mg/kg oxytocin and foot shock, 4.) medium dose group that received 0.3 mg/kg oxytocin and foot shock, and 5.) high dose group that received 1.0 mg/kg oxytocin and foot shock. Rats were treated with oxytocin (or vehicle) 30 min prior to exposure to fear conditioning. Rats were put into a Colbourn Precision fear-conditioning shock chamber, a plexiglass box with a metal grate floor, which delivered five foot shocks at an intensity of 0.6 mA. Twenty-four hours later, the rats were re-exposed to the chamber for 5 minutes, not shocked, and the freezing time was recorded via a motion detector. Results: Preliminary data suggests that the low dose of oxytocin (0.03mg/kg) decreases freezing relative to the untreated shock group. Conclusion: These data suggests that a specific dose of oxytocin (0.03mg/kg), administered i.p., can be used as a prophylactic pre-treatment to mitigate signs of fear.

This document is currently not available here.

Share

COinS
 
May 10th, 11:15 AM May 10th, 1:00 PM

Investigating the Effects of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

PUB NCR

Introduction: Oxytocin has been used as a post-treatment for PTSD. Previous research suggests that pre-treatment of intranasal oxytocin attenuates signs of fear in rats; however, the impact of intraperitoneal (i.p) oxytocin pre-treatment on signs of fear in rats is unknown. To further this research, we investigated the specific dose of oxytocin, administered (i.p), that will also alleviate signs of fear in rats. Methods: Male Sprague-Dawley rats, were split into five experimental groups (n=8 per group); 1.) control group treated with vehicle and no foot shock, 2.) shock group treated with vehicle and received foot shock, 3.) low dose group that received 0.03 mg/kg oxytocin and foot shock, 4.) medium dose group that received 0.3 mg/kg oxytocin and foot shock, and 5.) high dose group that received 1.0 mg/kg oxytocin and foot shock. Rats were treated with oxytocin (or vehicle) 30 min prior to exposure to fear conditioning. Rats were put into a Colbourn Precision fear-conditioning shock chamber, a plexiglass box with a metal grate floor, which delivered five foot shocks at an intensity of 0.6 mA. Twenty-four hours later, the rats were re-exposed to the chamber for 5 minutes, not shocked, and the freezing time was recorded via a motion detector. Results: Preliminary data suggests that the low dose of oxytocin (0.03mg/kg) decreases freezing relative to the untreated shock group. Conclusion: These data suggests that a specific dose of oxytocin (0.03mg/kg), administered i.p., can be used as a prophylactic pre-treatment to mitigate signs of fear.